@article{Soliman_De Sanctis_Yassin_Alshurafa_Ata_Nashwan_2022, title={Blood transfusion and iron overload in patients with Sickle Cell Disease (SCD): Personal experience and a short update of diabetes mellitus occurrence}, volume={93}, url={https://mattioli1885journals.com/index.php/actabiomedica/article/view/13330}, DOI={10.23750/abm.v93i4.13330}, abstractNote={<p>The conventional treatment of β-thalassemia (β-TM) patients is based on the correction of anemia through regular blood transfusions and iron chelation therapy. However, allogeneic hematopoietic stem cell transplantation (HSCT) remains the only currently available technique that has curative potential. Variable frequency and severity of long-term growth and endocrine changes after conventional treatment as well as after HSCT have been reported by different centers. The goal of this mini-review is to summarize and update knowledge about long-term growth and endocrine changes after HSCT in patients with β-TM in comparison to those occurring in β-TM patients on conventional treatment. Regular surveillance, early diagnosis, treatment, and follow-up in a multi-disciplinary specialized setting are suggested to optimize the patient’s quality of life (www.actabiomedica.it).</p>}, number={4}, journal={Acta Biomedica Atenei Parmensis}, author={Soliman, Ashraf T and De Sanctis, Vincenzo and Yassin, Mohamed and Alshurafa, Awni and Ata , Fateen and Nashwan , Abdulqadir}, year={2022}, month={Aug.}, pages={e2022291} }